 |
|
Rare Lung Disease Cells Indicate Higher Death Risk
January 17, 2008CINCINNATI-Large numbers of certain cells in the lungs of patients diagnosed with idiopathic pulmonary fibrosis may increase their chance of death, UC researchers have discovered.
According to a new study, increased numbers of neutrophil (pronounced new-tro-fil) cells-a type of white blood cell-in patients' lungs were associated with a 30 percent increased risk of mortality in the first year following diagnosis with idiopathic pulmonary fibrosis (IPF).
"A measure of cell types in the lungs of IPF patients at the time of diagnosis may allow us to determine their risk of death in the following year," says Brent Kinder, MD, assistant professor of medicine at the UC College of Medicine and pulmonologist with UC Physicians.
"This even takes into account other well-known measures of disease severity like age, whether or not the patient smokes and how well his or her lung functions during breathing tests," he adds.
Kinder co-authored the study, which is featured in the January issue of the journal Chest, with colleagues from the University of California, San Francisco (UCSF), and National Jewish Medical Center in Denver, Colo.
IPF is scarring of the lung. As the disease progresses, air sacs in the lungs become replaced by fibrotic scar tissue. Lung tissue becomes thicker where the scarring forms, causing an irreversible loss of the tissue's ability to carry oxygen into the bloodstream.
IPF is one of about 200 disorders called interstitial lung diseases (ILDs), which affect the thick tissue of the lung as opposed to more common lung ailments-such as asthma or emphysema-that affect the airways.
It is the most common form of ILD and affects about 128,000 people in the United States, with an estimated 48,000 new cases diagnosed each year. There currently are no proven therapies or cures for IPF.
Researchers discovered the link between neutrophils and IPF outcome using bronchoalveolar lavage. The technique involves passing a bronchoscope through the mouth of the patient and into the lungs. Saline is squirted into a small part of the affected lung and then recollected for examination.
The team evaluated the cell count of 156 people with IPF at the time the disease began to make its appearance.
"With this information, we can now work to identify neutrophil cells in patients' lungs and provide detailed information for more accurate diagnosis," says Kinder, who is also director of the newly established Interstitial Lung Disease Center at UC.
"It is our hope that this accurate prognostic information will become even more useful as effective treatments become available."
Kinder's research team included Talmadge King, Jr., MD, chair of internal medicine at UCSF and senior author of the study; Kevin Brown, MD, Marvin Schwarz, MD, and Alma Kervitsky from National Jewish Medical Center; and Joachim Ix, MD, from the University of California, San Diego.
The study was funded by grants from the National Heart, Lung and Blood Institute.
University of Cincinnati
"This even takes into account other well-known measures of disease severity like age, whether or not the patient smokes and how well his or her lung functions during breathing tests," he adds.
Kinder co-authored the study, which is featured in the January issue of the journal Chest, with colleagues from the University of California, San Francisco (UCSF), and National Jewish Medical Center in Denver, Colo.
IPF is scarring of the lung. As the disease progresses, air sacs in the lungs become replaced by fibrotic scar tissue. Lung tissue becomes thicker where the scarring forms, causing an irreversible loss of the tissue's ability to carry oxygen into the bloodstream.
IPF is one of about 200 disorders called interstitial lung diseases (ILDs), which affect the thick tissue of the lung as opposed to more common lung ailments-such as asthma or emphysema-that affect the airways.
It is the most common form of ILD and affects about 128,000 people in the United States, with an estimated 48,000 new cases diagnosed each year. There currently are no proven therapies or cures for IPF.
Researchers discovered the link between neutrophils and IPF outcome using bronchoalveolar lavage. The technique involves passing a bronchoscope through the mouth of the patient and into the lungs. Saline is squirted into a small part of the affected lung and then recollected for examination.
The team evaluated the cell count of 156 people with IPF at the time the disease began to make its appearance.
"With this information, we can now work to identify neutrophil cells in patients' lungs and provide detailed information for more accurate diagnosis," says Kinder, who is also director of the newly established Interstitial Lung Disease Center at UC.
"It is our hope that this accurate prognostic information will become even more useful as effective treatments become available."
Kinder's research team included Talmadge King, Jr., MD, chair of internal medicine at UCSF and senior author of the study; Kevin Brown, MD, Marvin Schwarz, MD, and Alma Kervitsky from National Jewish Medical Center; and Joachim Ix, MD, from the University of California, San Diego.
The study was funded by grants from the National Heart, Lung and Blood Institute.
University of Cincinnati
Pulmonary Fibrosis News and Current Pulmonary Fibrosis Events RSSNote to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in
Family, friends and neighbors remember Lisa Sandler Spaeth as an active mother of two in Potomac, Md., with a lot on the go, juggling her son's baseball games and her daughter's horseback-riding lessons with numerous committee obligations, organizing women's activities at her local synagogue.
Biomarkers identified for idiopathic pulmonary fibrosis
The first evidence of a distinctive protein signature that could help to transform the diagnosis and improve the monitoring of the devastating lung disease idiopathic pulmonary fibrosis (IPF) is being reported by University of Pittsburgh School of Medicine researchers in this month's edition of PLoS Medicine, an open-access journal of the Public Library of Science.
UCSF marks a milestone with 500th transplant in heart and lung program
UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung.
Smoking belies milder disease but worse prognosis for IPF patients
Smokers and ex-smokers with idiopathic pulmonary fibrosis (IPF), an untreatable progressive lung disease that usually leads to death within a few years of diagnosis, have a worse prognosis than non-smokers, according to research from London.
Researchers show that fibrosis can be stopped, cured and reversed
University of California, San Diego researchers have proven in animal studies that fibrosis in the liver can be not only stopped, but reversed.
Translational research patented first experimental treatment against idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis is a disease with unknown cause with a very severe prognosis; when detected, it is already in an advanced stage.
Molecular pathway appears crucial in development of pulmonary fibrosis
A study led by Massachusetts General Hospital (MGH) researchers may have found a key mechanism underlying idiopathic pulmonary fibrosis (IPF), a usually fatal lung disease for which transplantation is the only successful treatment.
Preventing lung scarring may extend lives of lung cancer patients
Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibody to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients - pulmonary fibrosis (scarring of the lungs), thereby extending patients' lives and improving their quality of life.
Experts predict high mortality rates from pulmonary fibrosis will continue to rise
Mortality rates from pulmonary fibrosis (PF) have increased significantly in recent years, and are predicted to continue to rise, according to researchers from the University of Colorado.
Scleroderma Outlook Improves as Survival Increases
Individuals with scleroderma are living significantly longer today, compared with 30 years ago, and the physicians who treat this rare disease of connective tissue hope the newer drugs now on the market may extend lives even further.
More Pulmonary Fibrosis News Articles
 | Taking Flight: Inspirational Stories of Lung Transplantation Lung Transplantation is still relatively new compared to other transplantation surgery. The first successful heart/lung transplant took place in 1981, with the first successful single lung transplant taking place in 1983. It was not until 1986 the first successful double lung transplant takes place. Even more recent is the living lobar transplant which the first successful one being in 1990. The... |
 | Cystic Fibrosis: Medical Care by David Michael Orenstein, Robert C. Stern, Beryl J. Rosenstein This practical, easy-to-use reference book is a must have for all physicians and medical care providers who deal with cystic fibrosis patients. Keep this book on hand for consistant and quick answers you need when diagnosing, treating, and managing cystic fibrosis... |
 | Cystic Fibrosis: A Guide for Patient and Family Written by Dr. David Orenstein, director of one of the nation's leading CF centers, this one-of-a-kind guide offers clear explanations and real-world advice on cystic fibrosis and its management. Here you'll find practical and reassuring information on day-to-day concerns--school, travel, exercise, nutrition, medication--as well as on physiological effects, long-term issues, and prospects for a... |
 | Advances in Pulmonary Fibrosis by John Simpson, Ann Millar Recent years have seen renewed interest in diffuse parenchymal lung diseases (DPLDs), which were formerly referred to as interstitial lung diseases (ILDs). This is reflected in the publication of many important and groundbreaking papers in this field. Knowledge, and easy access to it, is the key to understanding pulmonary fibrosis. Providing reviews of the published medical literature of the past... |
 | Cystic Fibrosis (Facts) by Ann Harris, Anne Thomson Cystic Fibrosis: The Facts provides a much needed simple and understandable source book about this disease. It is aimed at those living with Cystic Fibrosis (CF), either themselves or members of their families or their friends. The book explains clearly what is happening to the body in CF, what causes it and what treatment options are available for the different aspects of the disease. There... |
 | The Official Patient's Sourcebook on Idiopathic Pulmonary Fibrosis by James N. Parker This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to idiopathic pulmonary fibrosis (also alveolocapillary block; cryptogenic... |
 | Genetic Modulators of Pulmonary Function in Cystic Fibrosis & Genetic Susceptibility Factors of Emphysema (ACTA Biomedica Lovaniensia) by Jennifer S. Yarden This is a Ph.D. thesis. CF is one of the most common lethal autosomal recessive affecting the Caucasian population with an incidence of about 1 in 2500 births. Clinical manifestations are attributed to mutations in the CFTR gene, which encodes an epithelial chloride channel. Specific mutations can influence the severity and progression of CF disease, but wide variations within genetically... |
 | Idiopathic Pulmonary Fibrosis (Lung Biology in Health and Disease) A discussion of the epidemiology, clinical features, and differential diagnoses of idiopathic pulmonary fibrosis (IPF). Key topics include the role of polymorphonuclear leukocytes in the pathogenesis of pulmonary fibrosis, and current treatment options, including medical therapy and lung... |
 | Fibrosis Research: Methods and Protocols (Methods in Molecular Medicine) Leading investigators review the highlights of current fibrosis research and the experimental methodologies used uncover the mechanisms that drive it. In their discussion of research methodologies utilizing cultured cells to model various aspects of the fibrotic response in vitro, the authors describe the isolation, characterization, and propagation of mesenchymal cells, and highlight the... |
 | One Step at a Time by Jennifer Smith and Bradie Kvinsland "One Step at a Time" is a book, keepsake and guide for coping with a child's hospitalization. It offers a unique way for a parent to ask the right questions, record important medical information, and express joy, fear and hope during a very difficult time. And most important, it encourages parents to take care of themselves physically, emotionally and... |
| © 2008 BrightSurf.com |